Vismodegib CAS 879085-55-9

Producte Descripció:

Producte Nom:Vismodegib CAS 879085-55-9}

 

Sinònims:

2-Chloro-N-[4-}chloro-3-(2-piridinyl)phenyl]-4-(metilsulfonil)benzamide;BROMO-1-}NAPHTA

BenzaMide, 2-}chloro-N-[4-}chloro-3-(2-pyridinyl)phenyl]-4-(metilsulfonil)-;

VisModegib (GDC-0449);

 

Químic & Físic Propietats

Appearance:White to Off-White Solid

Assaig: 99%+

Ebullició punt:561.6±50.0 grau

Fusió punt:179-181 grau

Molecular Pes:421.3

Densitat:1.440

Pka:10.72±0.70

Estabilitat:Estable for 2 anys de data de compra as subministrat. Solucions en DMSO o etanol maig be emmagatzemat at -20} grau for up to 3 mesos.

 

Aplicació:

Vimodej targets SMO protein and inhibits Gli activation, thereby inhibiting downstream gene transcription and expression.For the treatment of locally progressive or metastatic basal cell carcinoma in adults who have recurred after surgery or are not well treated with surgery or radiotherapy; One of the most common skin cancers is basal cell carcinoma (BCC), which originates in the surface layer of the skin and does not cause pain to patients. The risk was greatest for skin diseases that were regularly exposed to the sun or ultraviolet light. The development and listing of Vimedji has brought good news to patients with BCC, and its clinical role is important and the target market is huge, and it has to grow into a "giant bomb" class (> $1 bilió) fàrmac en el futur.

 

 

 

Si tu ets interessats en nostre productes o tenir qualsevol preguntes, please feel free to contact us!

 

 

Productes sota patent són oferts per a R & D finalitat només. No obstant això, el final responsabilitat mentides exclusivament amb el comprador.

Etiquetes populars: VismodegiB Cas 879085-55-9, Fabricants, Proveïdors, Fàbrica, Buy, en estoc

• Un parell de: Tricina CAS 5704-04-1
• Següent: Trametinib CAS 871700-17-3